Skip to Content


Active Substance: insulin lispro
Common Name: insulin lispro
ATC Code: A10AB04
Marketing Authorisation Holder: Eli Lilly and Company Limited
Active Substance: insulin lispro
Status: Withdrawn
Authorisation Date: 1997-05-07
Therapeutic Area: Diabetes Mellitus
Pharmacotherapeutic Group: Fast acting human insulin analogue

Therapeutic Indication

For the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.  Liprolog is also indicated for the initial stabilization of diabetes mellitus.  Liprolog  is a short acting insulin and may be used in conjunction with a longer acting human insulin.  Liprolog is indicated for preprandial administration.

The marketing authorisation for Liprolog has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.